Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-Intron vs INTRON A in Adjuvant Melanoma
NCT03552549Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Aug 1998
- Primary completion
- Feb 2001
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2b in cutaneous melanoma (CM) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free Survival at 26 months. Started Aug 1998; status: terminated.
02
Drugs
peginterferon alfa-2b
03
Conditions
cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT03552549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03552549.